Summary of baseline characteristics of study patients
| Baseline parameters | Total (n=62) | Imatinib+vitamin D3 group (n=31) | Imatinib+placebo group (n=31) | P value | |
| Age (years) | 35 (28–45) | 34 (28–40) | 38 (29–48) | 0.23 | |
| Sex, n (%) | Male | 36 (58.1) | 19 (61.3) | 17 (54.8) | 0.61 |
| Female | 26 (41.9) | 12 (38.7) | 14 (45.2) | ||
| Duration of symptoms (months) | 1.5 (1-2) | 1.5 (1–2) | 2 (1–2.5) | 0.29 | |
| Spleen size (cm below the costal margin) | 11.5 (9–15) | 12 (10–15) | 11 (8–15) | 0.63 | |
| Liver size (cm below the costal margin) | 3.5 (2–6.3) | 5 (2–8) | 3.5 (2.5–4.3) | 0.76 | |
| Baseline haematological parameters | |||||
| Haemoglobin (g/dL) | 10.4 (9–11.8) | 10.5 (9–11.8) | 10.2 (8.9–12) | 0.84 | |
| Total leucocyte count (×109/L) | 153.5 (105–226.2) | 132 (91.5–242) | 178.8 (109.2–226.2) | 0.54 | |
| Platelet count (×109/L) | 330.5 (202–458) | 349 (185–458) | 328 (202–495) | 0.72 | |
| Peripheral blood blast (%) | 3 (2–4) | 3.5 (2–5) | 2.5 (2–4) | 0.37 | |
| Neutrophil (%) | 45 (39–58) | 47.5 (37–55) | 44 (39–60) | 0.81 | |
| Lymphocyte (%) | 3 (2–6) | 3 (2–6) | 3 (2–6) | 0.61 | |
| Monocyte (%) | 2 (1–2) | 2 (1–3) | 2 (1–2) | 0.59 | |
| Eosinophil (%) | 3 (2–5) | 3 (2–4) | 4 (2–5) | 0.41 | |
| Basophil (%) | 5 (4–7) | 5 (4–8) | 5 (4–7) | 0.93 | |
| Promyelocyte (%) (n=44) | 3 (1–4.5) | 2.5 (1–5) | 3 (2–4) | 0.67 | |
| Myelocyte (%) (n=60) | 23 (16–28) | 23 (17–27) | 23 (15–30) | 0.77 | |
| Metamyelocyte (%) (n=56) | 10 (7–15) | 10 (7–15) | 10.5 (7–15) | 0.82 | |
All parameters are expressed as median (IQR), except gender which is expressed in n (%).